|
|
|
Rare Diseases >> Abstract Details |
|
|
Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract |
Description of Invention:
|
This invention relates to the alleviation of symptoms of Th2-like cytokine mediated disorders, such as allergy, asthma, and to hyperinflammatory responses in the respiratory tract to infectious diseases and parasitic infections, including tuberculosis, schistosomiasis, leishmania, and filariasis.
This invention claims a variety of methods and uses of a chimeric molecule comprising a toxic moiety and a targeting moiety that specifically binds to a cell surface receptor for IL-13, to alleviate symptoms of a variety of respiratory disorders. This method has been proven successful in various mouse models in vivo.
Raj K. Puri et al. (FDA)
DHHS Reference No. E-296-2001/0 --
U.S. Provisional Application No. 60/337,179 filed 04 Dec 2001
PCT Application No. PCT/US02/00616 filed 28 Feb 2002, which published as WO 03/047632 on 12 Jun 2003
U.S. Patent Application No. 10/497,804 filed 04 Jun 2004
Internal Medicine
Internal Medicine-Therapeutics-Anti-Inflammatory (including Autoimmune) Internal Medicine-Therapeutics
For Additional Information Please Contact:
| David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
Web Ref: 679
Last Updated On: 11/02
|
|
|
|
|
|
|
|